210 related articles for article (PubMed ID: 19959313)
1. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.
Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF
J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313
[TBL] [Abstract][Full Text] [Related]
2. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
[TBL] [Abstract][Full Text] [Related]
3. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
[TBL] [Abstract][Full Text] [Related]
4. Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches.
Keire DA; Mans DJ; Ye H; Kolinski RE; Buhse LF
J Pharm Biomed Anal; 2010 Sep; 52(5):656-64. PubMed ID: 20233649
[TBL] [Abstract][Full Text] [Related]
5. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
[TBL] [Abstract][Full Text] [Related]
7. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
[TBL] [Abstract][Full Text] [Related]
8. Identification and purity test of heparin by NMR - a summary of two years' experience at the Medical Products Agency.
McEwen I; Amini A; Olofsson IM
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):65-72. PubMed ID: 20223191
[TBL] [Abstract][Full Text] [Related]
9. The use of SAX-HPLC-CD as a heparin screening strategy.
Chmielewski AJ; Stanley FE; Stalcup AM
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2619-23. PubMed ID: 21831728
[TBL] [Abstract][Full Text] [Related]
10. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography.
Limtiaco JF; Jones CJ; Larive CK
Anal Chem; 2009 Dec; 81(24):10116-23. PubMed ID: 19911825
[TBL] [Abstract][Full Text] [Related]
11. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
[TBL] [Abstract][Full Text] [Related]
12. Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay.
Sommers CD; Mans DJ; Mecker LC; Keire DA
Anal Chem; 2011 May; 83(9):3422-30. PubMed ID: 21449571
[TBL] [Abstract][Full Text] [Related]
13. Prediction of the oversulphated chondroitin sulphate contamination of unfractionated heparin by ATR-IR spectrophotometry.
Norwig J; Beyer T; Brinz D; Holzgrabe U; Diller M; Manns D
Pharmeur Sci Notes; 2009 Mar; 2009(1):17-24. PubMed ID: 19275869
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
[TBL] [Abstract][Full Text] [Related]
15. Characterization of currently marketed heparin products: key tests for quality assurance.
Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
[TBL] [Abstract][Full Text] [Related]
16. Novel and highly sensitive mixed-polymeric electrokinetic chromatography system for determination of contaminants and impurities of heparin samples.
Tripodi V; Flor S; Dobrecky C; Contin M; Lucangioli S
Electrophoresis; 2010 Oct; 31(21):3606-12. PubMed ID: 20967770
[TBL] [Abstract][Full Text] [Related]
17. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
Wielgos T; Havel K; Ivanova N; Weinberger R
J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
[TBL] [Abstract][Full Text] [Related]
18. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
[TBL] [Abstract][Full Text] [Related]
19. Characterization of currently marketed heparin products: key tests for LMWH quality assurance.
Ye H; Toby TK; Sommers CD; Ghasriani H; Trehy ML; Ye W; Kolinski RE; Buhse LF; Al-Hakim A; Keire DA
J Pharm Biomed Anal; 2013 Nov; 85():99-107. PubMed ID: 23917037
[TBL] [Abstract][Full Text] [Related]
20. Determination of dermatan sulfate and chondroitin sulfate as related substances in heparin by capillary electrophoresis.
Bendazzoli C; Liverani L; Spelta F; Prandi M; Fiori J; Gotti R
J Pharm Biomed Anal; 2010 Dec; 53(5):1193-200. PubMed ID: 20674212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
